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AbsTrACT
background several open-label studies have shown 
good effect of deep brain stimulation (DBs) in the caudal 
zona incerta (cZi) on tremor, including parkinsonian 
tremor, and in some cases also a benefit on akinesia 
and axial symptoms. The aim of this study was to 
evaluate objectively the effect of cZi DBs in patients with 
parkinson’s disease (pD).
Method 25 patients with pD were randomised to either 
cZi DBs or best medical treatment. The primary outcomes 
were differences between the groups in the motor scores 
of the Unified parkinson’s Disease Rating scale (UpDRs-
III) rated single-blindly at 6 months and differences in the 
parkinson’s Disease Questionnaire 39 items (pDQ-39). 
19 patients, 10 in the medical arm and 9 in the DBs arm, 
fulfilled the study.
results The DBs group had 41% better UpDRs-III 
scores off-medication on-stimulation compared with 
baseline, whereas the scores of the non-surgical patients 
off-medication were unchanged. In the on-medication 
condition, there were no differences between the groups, 
neither at baseline nor at 6 months. subitems of the 
UpDRs-III showed a robust effect of cZi DBs on tremor. 
The pDQ-39 domains ’stigma’ and ’aDL’ improved only in 
the DBs group. The pDQ-39 summary index improved in 
both groups.
Conclusion This is the first randomised blinded 
evaluation of cZi DBs showing its efficacy on pD 
symptoms. The most striking effect was on tremor; 
however, the doses of dopaminergic medications could 
not be decreased. cZi DBs in pD may be an addition 
to existing established targets, enabling tailoring the 
surgery to the needs of the individual patient.
InTroduCTIon
Deep brain stimulation (DBS) is an established 
treatment for patients with Parkinson’s disease 
(PD) when pharmacological therapy alone does 
not provide sufficient relief or is associated with 
disabling side effects.1 2 At present, the subtha-
lamic nucleus (STN) is the target of choice, but 
in some patients alternative targets, such as the 
ventral intermediate nucleus (VIM) of the thal-
amus or the globus pallidus internus (GPi), are 
preferred according to the symptomatic profile 
of PD or other patient-specific considerations.3 4 
Recently, a number of studies have revived DBS in 
the posterior subthalamic area (PSA), a brain target 
that was commonly used for PD and tremors during 
the lesional era.5–9 The PSA is situated ventral to the 
VIM, between the red nucleus and the STN. This is 
a functionally crowded area that harbours the zona 
incerta including the caudal zona incerta (cZi), the 
Forel’s fields, the lemniscus and the prelemniscal 
radiations, among many other structures and path-
ways.10 11 
Open-label studies have reported good results 
of DBS in various parts of the subthalamic area 
for different forms of tremor, including parkinso-
nian tremor.12–20 Furthermore, none of the studies 
above had reported on psychiatric side effects 
that resemble what had been described following 
STN DBS, such as hypomania, apathy, depression 
or suicide.21–25 One intriguing study compared in 
a non-randomised unblinded manner DBS in the 
STN with DBS in cZi and suggested the latter to 
be more effective, not only for tremor, but also for 
rigidity and bradykinesia.16
Hence, it was of interest to evaluate in a more 
objective manner the effects of DBS of the cZi in 
patients with PD who otherwise fulfilled the criteria 
for STN DBS in order to establish its potential effi-
cacy and its safety profile. The aim of the present 
work was thus to evaluate the effects of bilateral 
cZi DBS versus best medical treatment in a single-
blinded randomised manner in a group of patients 
with PD who were eligible for bilateral STN 
DBS. The two primary outcomes were (a) differ-
ences in off-medication scores of the motor part 
of the Unified Parkinson’s Disease Rating Scale 
(UPDRS-III) between medical and surgical groups at 
6 months, and compared with their respective base-
line scores, and (b) differences between the groups 
in quality of life rated on the 39 items of the Parkin-
son’s Disease Questionnaire 39 items (PDQ-39).
MATerIAls And MeThods
Patients
Patients who would normally be considered for 
bilateral STN DBS were eligible for participation in 
this study. All patients had previously undergone a 
123I FP CIT SPECT to support the diagnosis of PD. 
The inclusion criteria were thus the same as for STN 
DBS, that is, idiopathic PD, as diagnosed by a senior 
movement disorders neurologist according to the 
criteria of the UK Parkinson’s Disease Brain Bank26; 
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L-dopa-responsive symptoms (defined as >30% improvement 
in motor scores of the UPDRS-III), disabling motor fluctua-
tions with or without dyskinesias or disabling tremor; age <75 
years; no relevant psychiatric comorbidities or cognitive decline; 
normal brain MRI and absence of surgical contraindications. 
All patients underwent a formal neuropsychological evaluation, 
a standardised L-dopa challenge and a brain MRI to rule out 
atrophy or other contraindications for brain surgery. All patients 
were informed about the aim of the study and the possibility 
of having DBS in the ‘established’ STN target if they chose 
not to participate in the study. Informed consent was obtained 
according to the Declaration of Helsinki.
study design
Patients were randomised to either bilateral cZi DBS within 
1 month from inclusion or to best medical treatment (and, if 
needed, bilateral cZi DBS after 6 months). UPDRS-III on-med-
ication/off-medication was administered at baseline and at 6 
months on-medication/off-medication and on-stimulation/
off-stimulation by the same experienced evaluator (AF). The 
UPDRS-III scoring off-medication was done in the morning after 
withholding medication for 12 hours. The evaluation on-med-
ication was done after administration of an L-dopa dose 50% 
higher than the patient’s normal morning dose. The evaluations 
at 6 months were conducted in both on-medication and off-med-
ication states and on-stimulation/off-stimulation after the stimu-
lator had been switched off/on for 60 min.
All UPDRS-III evaluations were videotaped with the patients 
wearing head caps. The video documentations of UPDRS-III of 
each patient comprised 4–6 segments (baseline on-medication/
off-medication and 6 months on-medication/off-medication and 
on-stimulation/off-stimulation). The order of these segments was 
randomised and presented to two blinded experienced assessors 
(LF and MH) who were not involved in selection of patients, 
surgery, or follow-up, and who were unaware of the patient’s 
previous allocation. Two UPDRS items could not be evaluated 
on video: item 18 concerning speech and item 22 concerning 
rigidity. These two items from the unblinded UPDRS scoring 
were added to the blinded video-based scores of the motor 
UPDRS.
surgery
The surgical procedure has been described in detail previ-
ously.27 In summary, stereotactic implantation of the DBS elec-
trodes 3389 (Medtronic, Minneapolis, Minnesota, USA) was 
performed in local anaesthesia using the Leksell frame model G 
(Elekta Instruments, Linköping, Sweden). The brain target was 
identified anatomically on stereotactic thin-slice T2-weighted 
axial MR images. The target point lay slightly posteromedial to 
the visualised posterior tail of the STN on the scan showing the 
maximal diameter of the red nucleus (figure 1). An intraopera-
tive stereotactic CT scan was performed with the frame in place 
and fused with the preoperative stereotactic MRI for verifica-
tion of the electrode position (figure 2). If the position of the 
lead did not coincide with the intended target, the electrode was 
repositioned and a new CT scan performed. The implantable 
pulse generator (Kinetra/Activa PC, Medtronic) was implanted 
in the same surgical session. All procedures were performed 
by the same surgeon (PB). Microelectrode recording was not 
performed.
In the week after surgery, patients underwent in off-medi-
cation condition a systematic screening of electrode contacts 
to assess stimulation thresholds and effects on tremor, 
bradykinesia and rigidity, as well as stimulation-induced side 
effects. The contacts demonstrating the best effect in the 
absence of side effects were chosen for chronic stimulation. 
Stimulation settings and medications were evaluated and opti-
mised during the study period, and eventual adverse events 
were recorded.
outcome measures
The primary outcomes were the difference between groups at 
6 months in the motor scores of the UPDRS-III and in health-re-
lated quality of life rated on the PDQ-39.
Secondary outcome measures included changes between 
baseline and 6 months in subscores of the UPDRS-III (tremor, 
speech, bradykinesia and axial subscores) in each group, as well 
as changes in dyskinesia and motor fluctuation scores according 
to UPDRS-IV, and in levodopa-equivalent daily doses (LEDD) 
between baseline and 6 months.
Figure 1 The target point in the caudal zona incerta, medial to the tail 
of the subthalamic nucleus (sTN). Rn, red nucleus.
Figure 2 stereotactic intraoperative cT scan fused with stereotactic 
preoperative T2-weighted MRI scan demonstrating bilateral electrodes 
(arrows) implanted in the caudal zona incerta.
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statistics
Patient demographic and clinical characteristics are presented as 
mean±SD and range. A two-tailed t-test was used for continuous 
variables. The Wilcoxon signed-rank test for paired samples 
was used for non-parametric data, to compare preoperative 
and postoperative scores within the medical and surgical group. 
Mann-Whitney U test was used for unpaired non-parametric 
data in order to compare scores between the medical and the 
surgical group. A P value of <0.05 was considered statistically 
significant.
resulTs
Twenty-five patients met the inclusion criteria and accepted 
to be included in the trial. Of these 25 patients included and 
randomised, 6 could not or would not fulfil the trial: 4 patients 
(1 randomised to DBS and 3 to best medical management) quit 
directly after randomisation and did not wish to proceed. One 
patient randomised to DBS fell and broke her knee just before 
the surgery, and one patient refused to undergo evaluation with 
DBS turned off at 6 months. Hence, 19 patients (10 randomised 
to best medical management and 9 to DBS) fulfilled the trial and 
completed the evaluations at 6 months.
The patients’ demographic and clinical characteristics at base-
line are presented in table 1: there were no significant differ-
ences between the groups at baseline. Both groups showed good 
response to the L-dopa test preoperatively.
Main outcomes
Table 2 shows the scores of UPDRS-III between groups at 6 
months. The scores were significantly better for surgical patients 
on-stimulation off-medication compared with medical patients 
off-medication. In the on-medication condition, there were no 
significant differences in UPDRS scores between the two groups.
Table 3 shows the results of PDQ-39: the summary index was 
not different between medical and surgical groups, neither at 
baseline nor at 6 months. Compared with baseline, PDQ-39 
summary index was improved in the surgical group by 36.4% 
and in the medical group by 24.4%. In the surgical group, the 
improvement was significant concerning subdomains ‘ADL’ and 
‘stigma’, and in the medical group the improvement concerned 
only the summary index of the PDQ-39. At baseline, as well as 
at 6 months, the surgical group scored better than the medical 
group on the dimension ‘emotion’.
Table 1 Patients’ characteristics in medical and surgical groups at baseline
Medical group surgical group P value
Patients, n 10 9 NS
Male/female 8/2 7/2 NS
Age (years) 60.9±9.2 57±11.4 NS
Disease duration (years) 10.3±5.6 6.4±3 NS
LEDD at baseline (mg) 1043±516 1376±883 NS
UPDRS-III at baseline off-medication 42.4±14.5* 33.2±11.4** NS
UPDRS-III at baseline on-medication 20.6±11.9* 19.4±12.5** NS
Values represent mean±SD. 
*Within-group, P=0.001.
** Within-group, P=0.01.
LEDD,  levodopa-equivalent daily doses; NS, not  significant; UPDRS-III, Unified Parkinson’s Disease Rating Scale. 
Table 2 Mean±SD of Unified Parkinson’s Disease Rating Scale scores 
at 6 months in medical and surgical groups, respectively
off-medication on-medication
Medical group 37.2±12.2 21.8±13.4
Surgical group
  Off-stimulation 35.4±10.3 20.3±81.6
  On-stimulation 19.5±7.8 18.5±12.4
P values:
Medical group off-medication vs surgical group off-medication on-stimulation 
P=0.001.
Medical group on-medication vs surgical group on-medication on-stimulation: 
P=NS.
Within medical group: off-medication vs on-medication: P=0.001.
Within surgical group: off-medication off-stimulation vs off-medication–on-
stimulation: P=0.001.
Table 3 Parkinson’s Disease Questionnaire 39 items (PDQ-39) at 
baseline and at 6 months in medical and surgical groups, respectively
PdQ-39 domains
Medical group
Mean (sd)
surgical group
Mean (sd) P value
Mobility baseline 36.8 (21.5) 29.8 (18.1) NS
Mobility 6  months 28.5 (24.5) 20.6 (16.0) NS 
P value NS NS
ADL baseline 39.2 (19.0) 34.7 (18.1) NS
ADL 6  months 29.2 (26.6) 17.1 (12.6) NS 
P value NS 0.028
Emotion baseline 30.8 (16.2) 13.4 (9.7) 0.022
Emotion 6  months 24.5 (15.4) 8.8 (6.7) 0.022
P value NS NS
Stigma baseline 25.4 (16.0) 32.6 (22.9) NS 
Stigma 6 months 18.2 (11.6) 9.7 (9.4) NS
P value NS 0.027
Social baseline 7.5 (10) 8.33 (13.8) NS
Social 6  months 7.5 (12.1) 0.92 (2.8) NS 
P value NS 0.059
Cognition baseline 14.4 (15.0) 18.1 (17.5) NS
Cognition 6  months 12.5 (12.5) 13.2 (14.1) NS 
P value NS NS
Communication baseline 13.3 (16.75) 13.0 (18.7) NS
Communication 6  months 10.8 (14.2) 13.0 (8.4) NS 
P value NS NS
Body baseline 32.5 (25.0) 32.4 (24.5) NS
Body 6  months 21.7 (18.5) 20.4 (17.2) NS 
P value NS NS
PDQ SI baseline 25.0 (8.3) 22.8 (13.2) NS
PDQ SI 6  months 18.9 (9.85) 14.5 (9.5) NS 
P value 0.028 0.038 
PDQ SI, Parkinson’s Disease Questionnaire Summary Index; NS, not significant.
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secondary outcomes
Table 4 shows the values of selected items of the UPDRS-III 
and values for LEDD and UPDRS-IV (dyskinesia). Tremor 
improved markedly and akinesia moderately in the surgical 
group on-stimulation off-medication compared with the medical 
group off-medication. There were no differences between the 
groups in speech, axial symptoms, dyskinesia or in LEDD. When 
comparing the scores at 6 months with the scores at baseline in 
each group, total UPDRS-III scores as well as scores of subitems 
tremor and akinesia still showed good improvement on-medica-
tion versus off-medication in both groups.
When comparing UPDRS-III scores within the surgical group 
only, between on-stimulation and off-stimulation conditions at 6 
months, there was a significant improvement mainly in tremor 
and moderately in akinesia.
Considering motor fluctuations, the majority of patients had 
mild fluctuations: at baseline, four patients in the surgical group 
and nine patients in the medical group reported predictable off 
periods (UPDRS-IV, item 36). Three patients in the surgical 
group and nine in the medical group reported unpredictable off 
periods (item 37). One patient reported sudden off periods in 
the medical group (item 38). The mean off-time score (item 39) 
was 0.9±0.9 in the surgical group and 1.6±0.8 in the medical 
group at baseline (P=NS). No statistically significant changes 
were seen within or between the groups at 6 months follow-up 
in any of the subitems 36–39.
Adverse events
In the surgical group, adverse events included a deep venous 
thrombosis in one patient 3 months after surgery that was treated 
successfully. No adverse events were encountered or reported in 
the medical group.
stimulation parameters
Mean stimulation parameters at 6 months were 2.48±0.43 
V; 152.2±10.3 Hz; 63.3±9.7 µs. Seven patients had monop-
olar and two bipolar stimulation. The most used contacts of 
the quadripolar electrode were the two middle contacts. No 
patient had the most proximal contact as a cathode. The active 
contacts (cathodes) for each individual patient with coordinates 
in relation to the midcommissural point are shown in figure 3. 
In relation to the visible posterior tail of the STN (pSTN), the 
active contacts were located at a mean of 1.9±1.1 mm medi-
ally, 0.6±0.5 mm posteriorly and 1.9±1.2 mm dorsally. The 
mean vectorial distance from the active contact to the pSTN was 
3.1±0.8 mm. In relation to the midcommissural point, the active 
contacts were located 2.5±1.2 mm below, 7.0±0.4 mm poste-
rior and 11.6±1.1 mm lateral.
dIsCussIon
In this observer-blinded study on patients with advanced PD 
randomised to DBS in the cZi or to best medical management, 
it was shown that DBS in the cZi was safe and efficient. At 6 
months, operated patients had 45% improvement of UPDRS-III 
scores off-medication on-stimulation compared with their 
off-stimulation condition, and 41% improvement compared 
with their baseline UPDRS-III scores. When compared with the 
non-surgical patients off-medication, the DBS-treated patients 
had 47% better UPDRS motor scores. There were no differ-
ences between the groups in the on-medication condition. The 
PDQ-39 summary index showed similar improvement in both 
groups at 6 months: the medical group improved by 24% and 
the DBS group by 36%.
rationale for the study
Two large reviews of published papers on DBS of the PSA and 
cZi for various movement disorders19 20 have concurred in that 
this procedure seems to be quite efficient for tremor. One review 
hinted at the need for blinded evaluations,19 and the other 
review pointed to the need for quality-of-life assessments of 
patients.20 It is interesting to note that open-label studies that 
focused specifically on patients with PD undergoing cZi DBS 
reported a very positive effect on other symptoms than tremor: 
Carillo-Ruiz et al14 evaluated five patients and reported that the 
UPDRS-III was improved by 65%, with a 90% improvement in 
tremor, 94% in rigidity and 75% in bradykinesia. In a non-ran-
domised open-label sequential study, Plaha et al16 compared 
the effects of DBS in the STN (17 electrodes) and the cZi (27 
electrodes) and reported that the best effect was achieved in the 
cZi with a reduction of contralateral UPDRS-III score by 76%, 
tremor 93%, rigidity 76% and bradykinesia 65%. Nonethe-
less, according to the Movement Disorder Society task force on 
DBS for PD, only DBS targeting the STN or the GPi qualify 
as evidence-based procedures for PD.28 Hence, it was desirable 
Table 4 Mean±SD scores of selected items of Unified Parkinson’s Disease Rating Scale (UPDRS-III), dyskinesia scores (UPDRS-IV) and levodopa-
equivalent daily doses (LEDD), at baseline and at 6 months in medical group on-medication/off-medication, and in surgical group on-medication/
off-medication on-stimulation/off-stimulation
Medical group surgical group
baseline 6 months baseline 6 months
off-
medication
on-
medication
off-
medication
on-
medication
off-
medication
on-
medication
off-
medication
off-
stimulation
on-
medication
off-
stimulation
off- 
medication
on-
stimulation
on-
medication
on-
stimulation
Tremor (items 20–21) 8.3±6.4 2.1±3.9 6.9±5.6 2.7±4.7 5.1±3.4 2.3±4.2 6.1±4.6 2.1±4.2 0.4±0.5 0.4±0.8
Speech (item 18) 1.3±0.7 0.9±0.5 1.2±0.8 0.7±0.5 1.2±0.7 0.8±0.7 1.3±0.7 1±0.7 1.2±0.7 0.9±0.6
Akinesia (items 22–26) 15.8±5.6 9.1±5.1 14.4±4.4 7.9±5.4 14.3±6.6 10±6.1 15.7±6.3 9.1±3.3 9.7±5 10.1±6.6
Axial (items 27–31) 4.4±2.4 1.4±1.3 3.9±2.8 1.8±1.8 2.8±1.9 1.3±1 2.4±1.9 1.4±1.2 2.0±1.4 1.8±2.0
Dyskinesia 1.7±2.9 1.5±2.6 1.5±2.1 1.1±0.3
LEDD (mg) 1043±516 1180±548 1376±883* 1054±488*
Significant P values:
Medical group off-medication vs surgical group off-medication on-stimulation: tremor P=0.001; akinesia: P=0.015.
Surgical group off-medication scores at baseline vs off-medication on-stimulation scores at 6 months: tremor P=0.002; akinesia: P=0.026.
*One patient in surgical group had 8 mg of trihexyphenidyl, both at baseline and at 6 months follow-up.
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to establish in an objective manner whether cZi DBS was effi-
cient for PD and whether it was better than medication alone. 
It was also important to analyse its effect profile on the various 
symptoms of PD, and its impact on quality of life, in a similar 
way to what Deuschl et al did in their seminal publication from 
2006 comparing STN DBS versus best medical management2 at 
6-month follow-up. Therefore, we chose to include in this trial 
patients with PD who would otherwise qualify for STN DBS.
effect profile of cZi dbs on Pd symptoms
In analogy to most open-label reports,12 15 17 27 29 cZi DBS 
had a profound effect on tremor in our patients. There was a 
92% improvement in tremor scores when comparing DBS on 
versus baseline, and 93.4% improvement when comparing DBS 
on versus off at 6 months. Indeed, this is not surprising since 
high-frequency stimulation targeting the PSA and especially the 
area of the cZi will affect the cerebellothalamic fibres which are 
here concentrated in a small area, forming a bottleneck, before 
dispersing into the VIM thalamus.30–36 This would also explain 
the relatively modest level of energy needed in our patients to 
obtain a satisfactory effect on tremor, when stimulating this area 
(2.5 V in average).
The off-medication akinesia items of UPDRS-III showed 32% 
improvement between DBS on and baseline, and 38% improve-
ment between DBS on and DBS off. This degree of improvement is 
less than what has been reported in other open-label non-blinded 
studies of DBS in PSA and cZi,14 16 and underscores the impor-
tance of blinded clinical evaluations in surgery for movement 
disorders, especially when investigating ‘new’ brain targets for 
DBS. Interestingly, the level of improvement in our study was 
not much different from what was shown in similar randomised 
studies of bilateral STN DBS, where Deuschl et al2 reported an 
improvement of 41% of UPDRS-III at 6 months in the German 
multicentre trial, and Williams et al37 reported 36.2% improve-
ment at 12 months in the British multicentre ‘PD SURG’ trial.
Finally, in our study, axial items and items related to speech 
and dyskinesia did not show any differences between groups, 
nor between on-stimulation and off-stimulation in the DBS 
group. Also, the LEDD were unchanged between groups and 
within groups, although there was a non-significant tendency for 
a reduction of LEDD in the surgical group. Hence, at variance 
with what is known from studies on STN DBS, our patients with 
cZi DBS remained on practically the same doses of dopaminergic 
medications at 6 months as before surgery.
strength and limitations of our study
To the best of our knowledge, this is the first study on DBS in 
the cZi using a randomisation between a medical and a surgical 
group, and an observer-blinded evaluation. On the other hand, 
we are aware of the limited number of patients in this study: it 
Figure 3 Fused axial cT-MRI scans at the level of the active contact bilaterally in all operated patients. coordinates are given in relation to the 
midcommissural point.
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was not straightforward to recruit participants because, since the 
patients had to be eligible for the established STN DBS proce-
dures, several patients who were cleared for surgery and who 
were informed as per protocol that cZi DBS was an investiga-
tional target opted to have DBS in the more established STN 
target instead.
At baseline, disease duration was 4 years shorter on average in 
the surgical group than in the medical group, and the scores of 
UPDRS-III off-medication were lower. These differences were, 
however, not statistically significant, which could be due to the 
small sample size and/or large SD. This difference can also be 
explained by our non-stratified randomisation. Furthermore, at 
the 6-month follow-up, the differences in off-medication scores 
of UPDRS-III between groups had decreased and remained not 
significant.
Another limitation of our study is the relatively short follow-up 
of 6 months, but this was similar to the length of follow-up of 
the first randomised study comparing STN DBS to best medical 
management.2 Besides, it would be difficult to ethically justify 
withholding any surgery for longer than 6 months in patients 
with advanced disease who were eligible for surgery but who 
were in the medical arm.
The place of cZi dbs in surgery for Pd
Our study confirmed a strong effect of DBS in the cZi on parkin-
sonian tremor and moderate effect on bradykinesia. Therefore, 
this brain target may be considered in tremor-dominant parkin-
sonian patients who for various reasons may not be eligible for 
bilateral STN or GPi DBS. DBS in cZi can also be performed 
unilaterally if needed. Concerning VIM versus cZi DBS, our 
experience27 38 39 and that of others34–36 is that cZi DBS can be 
more efficient and more effective than VIM DBS. Additionally, 
as demonstrated in this study, DBS in cZi does have an effect, 
although moderate, on bradykinesia. Finally, compared with 
thalamic VIM DBS, cZi is also a target with more closely related 
anatomical structures that are visible on MRI, thereby allowing 
direct anatomical targeting as shown in figures 1 and 2.
In our practice of DBS, the cZi has now replaced the VIM 
both for selected patients with PD as well as patients with other 
tremor disorders. The fact that PD medications are not decreased 
lends this target to be used for unilateral DBS in patients with 
asymmetric parkinsonism.
ConClusIons
In this observer-blinded study on patients with advanced PD 
randomised to DBS in the cZi or to best medical management, 
it was shown that DBS in the cZi was efficient. The powerful 
effect of cZi DBS on tremor was confirmed. There was a modest, 
although significant, improvement on akinesia but not of the 
same magnitude as the improvement reported following STN 
DBS. Future reports will provide data on longer-term follow-up. 
Also, further studies are needed in order to determine the role 
of cZi DBS in the therapeutic armamentarium for PD, especially 
in relation to STN DBS. What can be stated so far is that the 
cZi as a target for DBS in PD will be an addition to the existing 
established targets, which may increase the possibility to tailor 
the surgery to the needs of the individual patients.
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